Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06843005
Recruiting Not applicable

Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease

NCT06843005 · tracked via the Priya Life Science China tracker
Sponsor
Zhang longjiang,MD
Phase
Not applicable
Started
2025-02-28
Last updated
2026-03-24

Condition(s) studied

Major Adverse Cardiovascular Events (MACE)PreventionCoronary Artery Disease(CAD)CT Angiography

Investigational drug(s) / intervention(s)

Coronary Computed Tomography AngiographyCurrent clinical guidelines

Coronary Computed Tomography Angiography: Based on the assessment of plaque progression after follow-up CCTA examination, patients will be given either intensive treatment or routine treatment.

Current clinical guidelines: Patients will be treated according to the 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes.

Study summary

The primary objective of this study is to evaluate whether a management strategy based on coronary computed tomography angiography (CCTA) for patients with non-obstructive coronary artery disease can improve the LDL-C target achievement rate compared to a traditional management strategy without follow-up CCTA, thereby reducing the incidence of major adverse cardiovascular and cerebrovascular events over a 3 years period, including all-cause mortality, myocardial infarction, ischemia driven revascularation and stroke.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age between 18 and 80 years old; 2. Known patients with non-obstructive coronary artery disease (disease duration ≥2 years); 3. Patients who agree to undergo follow-up CCTA examinations and cooperate in completing follow-up observations. Exclusion Criteria: 1. Patients who have experienced ACS or PCI/CABG; 2. Patients who have experienced adverse cardiovascular and cerebrovascular events; 3. Patients who have undergone follow-up CCTA or DSA examinations before enrollment; 4. Patients with severe hepatic and renal dysfunction; 5. Patients with contraindications to CCTA examinations; 6. Patients with poor initial CCTA image quality or data loss.

Primary outcome measure(s)

  • Major adverse cardiovascular and cerebrovascular event — 36 months after baseline
    Record the number of participants experiencing major adverse cardiovascular and cerebrovascular event such as all-cause mortality, non-fatal myocardial infarction, ischemia driven revascularation and stroke

Trial sites (1)

FacilityCityRegionStatus
Research Institute Of Medical Imaging Jinling Hospital Nanjing Jiangsu Recruiting

More Zhang longjiang,MD trials in China

Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population Recruiting

Other trials for the same condition

Effectiveness of an AI-Enabled Mobile Intervention on Lifestyle Behaviors and Maternal-Infant Health Starting soon
Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography Recruiting
Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) Recruiting
PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients Recruiting
Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06843005 on ClinicalTrials.gov ↗ ← All trials in China